Science Implants PRIMA Vision Chip in First Stargardt Patient

Max Hodak, CEO of Science Corporation, has revealed that the vision-restoring chip PRIMA has been implanted in a Stargardt disease patient for the first time. The announcement was made on stage at TechCrunch Disrupt on October 13, 2026. In reporting by TechCrunch AI’s Aisha Malik, his background as co-founder and former president of Neuralink was noted, along with how the PRIMA effort fits into the company’s brain-computer interface vision.

The company has so far commercialized PRIMA in Europe for patients blinded by geographic atrophy, the end-stage form of age-related macular degeneration. The latest implant is an attempt to extend the indication to genetic disease, and was performed in May 2026 as part of an ongoing clinical trial at Sydney Eye Hospital in Australia. The patient reportedly recognized letters during the first rehabilitation session and progressed to reading words in the second session.

Overview of PRIMA and the Implant Procedure

PRIMA is a small chip implanted behind the retina where photoreceptors have degenerated. It measures 2mm x 2mm, and surgery takes about one hour to complete. Patients wear glasses equipped with a camera, and an external camera captures images of the outside world and transmits them to the chip. The chip functions as an artificial photoreceptor, electrically stimulating the surviving inner retina to send signals to the brain via the optic nerve.

On stage, Hodak explained the nature of vision as follows.

The retina is part of the central nervous system. We consider cochlear implants, retinal prostheses, motor prostheses, these are all different types of BCIs.

This reflects the idea that by viewing the retina as part of the central nervous system, retinal prostheses can be positioned as a form of BCI, just like cochlear implants and motor prostheses. He also addressed signal processing in vision.

That’s all vision is to the brain, and so if you can get the optic nerve to signal the rest of the brain correctly, then you can provide vision to it.

For the brain, vision is nothing more than electrical activity traveling through the optic nerve. The logic that vision can be restored if the optic nerve signals correctly underpins PRIMA’s design philosophy.

First Implant Case in Stargardt Disease

Stargardt disease is a hereditary eye disease that affects the outer retina, causing light-sensing cells to gradually die. Meanwhile, the inner retina that relays visual signals to the brain may remain preserved. As the condition progresses, a blind spot appears in the center and expands over time. About 150,000 people worldwide are said to live with visual impairment from the disease. No curative treatment has been established to date.

Science Corporation believes PRIMA may be suited to this pathology. That is because the chip can substitute for outer retinal function while leveraging the inner retina and optic nerve pathway. This case is the first clinical test of that hypothesis. The trial at Sydney Eye Hospital is ongoing, and the company is looking toward applications across multiple diseases.

Post-implant vision is limited but functional. According to Hodak, the current device covers only part of the central visual field.

It is not a big field of view color vision. It’s a patch in their central vision where it’s black and white, but it is sharp.

The field of view is as narrow as looking through a straw, and vision is black and white rather than color. At the same time, it is high-contrast and sharp, at a level that allows recognition of several letters at a time. The patient’s progress from letters to words is consistent with these characteristics.

Commercialization in Europe and Background to

Indication Expansion

PRIMA is at a stage where it is commercially available in Europe for patients blinded by geographic atrophy. Geographic atrophy is an advanced form of age-related macular degeneration, a field where patient numbers are growing with aging. The company’s achievement of practical use first in this indication means it has moved ahead on regulatory compliance, manufacturing, and building a rehabilitation system.

Expansion into Stargardt disease is also an attempt to overcome differences in target age group and pathology. While geographic atrophy mainly affects older adults, Stargardt disease is a genetic disorder that begins and progresses at a young age. If indications broaden, new requirements will arise alongside an expanded patient population, including long-term durability of the device and compatibility with growing eyes.

The approach combining an external camera with glasses shares many design challenges with wearable devices such as those discussed in Snapdragon Reality Elite, New Chip for AR/MR. Wearing comfort, weight, heat generation, and stability of wireless transmission directly affect clinical outcomes. For visual quality as well, as with image reproduction debates like LG OLED evo, Creator Original Picture Mode with Prime Video, optimizing resolution and contrast is important. PRIMA’s black-and-white, high-contrast sharpness can be seen as a design choice that prioritizes readability over color reproduction.

Technical Challenges Toward a Wider Field of View

The company cites expanding the field of view as the next step. Hodak explained that the current 2mm-square chip is limited to a patch of central vision, and a larger implant will be needed. Because the eyeball is curved, enlargement requires conforming to that curvature. In addition, miniaturizing electrodes is essential to increase visual detail. The smaller the electrodes, the closer the resolution may come to native vision.

Enlargement and miniaturization are also conflicting demands. Increasing area while raising electrode density complicates wiring, power supply, and heat management. Biocompatibility and long-term stability at the implant site must also be verified. On the operational side of clinical trials, a phased testing and distribution framework like that suggested by GNOME OS Test Center, Inspired by Apple TestFlight offers a useful reference. Trials of medical devices also require methods that progressively expand functionality while confirming safety.

Hodak’s expansive view of BCI points to broader medical applications beyond computer operation. The perspective that treats retinal prostheses, cochlear implants, and motor prostheses all as BCIs provides a framework for handling electrical interventions in the nervous system comprehensively. In this framework, vision restoration is a waypoint in BCI development, positioned as a foundational technology for future central nervous system interfaces.

Current Status of the Clinical Trial and

Future Focus

The trial at Sydney Eye Hospital is at a stage of accumulating early data on both safety and efficacy. The patient’s progress from letters to words in this case is one indicator that the device can transmit visual information to the brain. However, generalizing from a single case will require accumulating more cases and long-term follow-up. Verification using multifaceted measures — quantitative assessment of visual acuity, reading speed, and improvement in daily activities — will be the future focus.

On the regulatory side, the track record of commercialization in Europe serves as a reference point, but expanding indications will require additional clinical data. Results from the trial in Australia could influence approval strategies in other regions. On the manufacturing side, mass-production technologies for curved, large implants and fine electrodes will be challenges. Improvements to the camera and image processing on the glasses side are also factors that shape the visual experience.

Science Corporation’s move is also notable in the context of BCI diversification by a leader from Neuralink. Beyond direct implantation into the brain, the approach of intervening from the retina at the periphery of the central nervous system can be seen as a strategy that balances invasiveness and efficacy. By setting a clear goal of restoring the function of vision, it also appears aimed at demonstrating technological maturity in stages.

Editorial Opinion

In the short term, we see the first implant in Stargardt disease accelerating the expansion of indications in clinical trials. This is because operational expertise gained from commercializing the device for geographic atrophy in Europe can be transferred to trial design and rehabilitation methods for genetic disease. Over the next 3 to 6 months, the focus will be on growth in case numbers and quantitative reporting on reading tasks. We also expect improvements in image processing and transmission stability on the glasses side to emerge as demands from clinical practice.

In the long term, we believe success or failure in widening the field of view and miniaturizing electrodes will be the branching point for wider adoption. If curved conformability and higher density can be achieved together, applications could expand from a patch of central vision to practical reading and face recognition. In 1 to 3 years, long-term safety data in pediatric and young-onset cases will accumulate, and insurance reimbursement and rehabilitation infrastructure will likely come under discussion. The company’s broad view of BCI is also likely to encourage spillover into sensory prostheses beyond vision.

Our question from the editorial team is where the yardstick for vision restoration should be placed. Beyond whether letters can be recognized, how should independence in daily life such as mobility and work be measured. How can the constraints of black-and-white, narrow-field vision be translated into value users can accept. How will patients and clinicians build consensus on the trade-off between invasiveness and benefit brought by larger devices.

References

• “Science Corporation implants its vision-restoring chip in its first Stargardt disease patient”, by Aisha Malik — TechCrunch AI, 2026-10-13T23:13:31.000Z (ARR)
• Source URL: https://techcrunch.com/2026/10/13/science-corporation-implants-its-vision-restoring-chip-in-its-first-stargardt-disease-patient/